The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,650.00
Ask: 1,749.00
Change: 0.00 (0.00%)
Spread: 99.00 (6.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: GlaxoSmithKline says on track for consumer demerger

Wed, 09th Feb 2022 08:21

(Alliance News) - Pharmaceutical firm GlaxoSmithKline on Wednesday said it generated stable revenue in 2021 and is on track to demerge a "new world-leading" GSK Consumer Healthcare business by mid-2022.

For 2021, total sales were GBP34.11 billion, up slightly from GBP34.10 billion in 2020 and pretax profit was down to GBP5.44 billion from GBP6.97 billion. The revenue figure was in line with market forecasts.

Adjusted operating profit was GBP8.82 billion in 2021, down from GBP8.91 billion in 2020.

Glaxo declared a 23 pence per share dividend for the fourth quarter, raising the total payout for 2021 to 80p.

Looking ahead for 2022, new GSK - meaning excluding the consumer business - expects sales to grow by between 5% to 7% at constant exchange rates and adjusted operating profit to grow by between 12% to 14% at constant currency as compared with 2021.

Assuming global economies and healthcare systems approach normality as the year progresses, Glaxo said it expect sales of Specialty Medicines to grow 10% at constant currency and sales of General Medicines to show a slight decrease. Glaxo said this was "primarily reflecting increased genericisation" of established Respiratory products. Vaccines sales are expected to grow at a low teens percentage at for the year as a whole.

"We have ended the year strongly, with another quarter of excellent performance driven by first-class commercial execution, and we enter 2022 with good momentum. This is going to be a landmark year for GSK, with a step-change in growth expected and multiple R&D catalysts, including milestones on up to 7 key late-stage pipeline assets. 2022 is also the year when we demerge our world-leading Consumer Healthcare business," Chief Executive Officer Emma Walmsley said.

"At our capital markets event later this month, we will set out the future growth ambitions and highly attractive financial profile of this business, and the outstanding opportunity it provides for shareholders," Walmsley added.

Glaxo said the capital markets day on February 28 will provide detailed financial information for GSK Consumer Healthcare.

The company's update on the demerger follows its rejection of three bid approaches for the consumer business by Unilever.

Glaxo shares were up 0.2% early Wednesday.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.5% at 7,602.75

----------

Hang Seng: up 2.1% at 24,829.99

Nikkei 225: closed up 1.1% at 27,579.87

S&P/ASX 200: closed up 1.1% at 7,268.30

----------

DJIA: closed up, 1.1%, at 35,462.78

S&P 500: closed up 0.8% at 4,521.54

Nasdaq Composite: closed up 1.3% at 14,194.46

----------

EUR: flat at USD1.1410 (USD1.1413)

GBP: soft at USD1.3545 (USD1.3551)

USD: down at JPY115.45 (JPY115.60)

Gold: firm at USD1,826.55 per ounce (USD1,825.73)

Oil (Brent): up at USD90.61 a barrel (USD90.28)

(changes since previous London equities close)

----------

ECONOMICS AND GENERAL

----------

Wednesday's key economic events still to come

0700 EST US MBA weekly mortgage applications survey

1000 EST US monthly wholesale trade

1030 EST US EIA weekly petroleum status report

----------

UK Prime Minister Boris Johnson will face members of Parliament on Wednesday after tinkering with his top team as he looks to stave off a confidence vote and lay the foundations for the next election battle. After months of being dogged by partygate allegations and a fresh controversy over his Jimmy Savile remarks, Johnson opted to embark on a mini-reshuffle on Tuesday as he attempts to regain his grip on power. Expected to join the PM on the frontbench for Prime Minister's Questions is new Chip Whip Chris Heaton-Harris. The long-time ally of Johnson replaces Mark Spencer, who was moved to Leader of the Commons after a series of missteps in managing the Conservative parliamentary party. Spencer's predecessor Jacob Rees-Mogg was shuffled into the newly minted role of Minister for Brexit Opportunities, in a move seen as an attempt to appease the Tory right-wing faction.

----------

Germany's trade surplus narrowed for the fifth year in a row in 2021, as a global supply crunch hampered exports, including in its key auto sector. The trade balance of Europe's biggest economy showed a surplus of EUR173.3 billion last year, down from EUR180.4 billion in 2020, the federal statistics office Destatis said.

----------

BROKER RATING CHANGES

----------

JPMorgan cuts Rightmove to 'underweight' (neutral) - price target 565 (753) pence

----------

JPMorgan cuts Auction Technology to 'neutral' (overweight) - price target 1,041 (1,471) pence

----------

Barclays cuts Chemring to 'equal weight' (overweight) - price target 300 (380) pence

----------

Barclays cuts boohoo to 'underweight' ('equal weight') - target 85 (135) pence

----------

COMPANIES - FTSE 100

----------

Barratt Developments said it delivered an excellent first half driven by a strong rebound in construction activity in the UK. For the six months to December 31, revenue was GBP2.25 billion, up from GBP2.49 billion at the same time in 2020 and pretax profit edged higher to GBP432.6 million from GBP430.2 million. Barratt declared an interim dividend of 11.2 pence, up from 7.5p. Total completions were down to 8,067 homes from 9,077 - reflecting the "unusually high" completions in the prior period. The UK's largest housebuilder by volume said it is on track to deliver total home completions of 18,000 to 18,250 in financial 2022, an increase of 250 homes on previous guidance and in excess of the total home completions delivered in financial 2019. "Macro economic uncertainties remain, most notably around rising inflation and interest rates in the wider UK economy. As a business we also face higher taxation, the ongoing challenges around build cost inflation and the future withdrawal of Help to Buy, which will begin to impact reservations in Autumn 2022, as the scheme draws to a close in March 2023," said Chief Executive Officer David Thomas.

----------

Anglo American said its new Aquila steelmaking metallurgical coal mine is on schedule and on budget, marking the project's final stages of construction and commissioning. The mine, located near Middlemount in central Queensland in Australia, extends the life of Anglo American's existing Capcoal underground operations by seven years, after the company's nearby Grasstree mine reached its end of life in recent weeks. Themba Mkhwanazi, CEO of Bulk Commodities, said: "We have delivered the Aquila project on time and within our budgeted attributable cost of USD226 million. This new mine will have a total average annual saleable production of around five million tonnes of premium quality hard coking coal and benefits from low capital intensity as we are using the existing infrastructure and systems from our adjacent operations. Aquila offers us highly attractive returns and margins at conservative long term consensus prices."

----------

COMPANIES - FTSE 250

----------

Homewares retailer Dunelm raised its interim dividend by 17% and declared a special payout, amid strong half-year results. Dunelm will pay 14.0 pence per share for the six months that ended December 25, up from 12.0p a year before. It also will pay a special dividend of 37.0p, which it said was "to return to leverage in line with published capital policy". Dunelm said pretax profit in the half-year was GBP140.8 million, up 25% on GBP112.4 million a year before, on GBP795.6 million in revenue, up 11% on GBP719.4 million. Gross margin improved by 80 basis points, the retailer said, due to higher full-price sales in the recent period and the comparison period being hurt by store lockdowns. Dunelm said full-year pretax profit will be in line with recently upgraded consensus, which it put at GBP206 million.

----------

COMPANIES - OTHER UK

----------

Talks between mutual insurers Royal London and LV= over a potential merger have ended with both sides walking away. The mutuals started discussions shortly after an attempted takeover of LV= by private equity firm Bain Capital in December failed to win enough support from its 1.2 million members. But on Wednesday, Royal London appeared to suggest it had been misled by LV= over the company's need to merge or risk going bust, whilst LV= said the different business models made a merger impossible. Royal London Chief Executive Barry O'Dwyer said: "Mutuals are owned by their customers and are run for their benefit. "Our offer to preserve LV='s mutuality through a merger with Royal London was based on an understanding that LV= did not have a viable future as an independent company." LV= said a deal would not be possible because "our different mutual models mean such a merger would not be in the best interests of LV= members."

----------

COMPANIES - GLOBAL

----------

Honda Motor's profit dropped 32% in the last quarter amid rising material costs and a shortage of computer chips. The Japanese car maker reported a profit for the three months to December of JPY192.9 billion, about GBP1.1 billion, down from JPY284 billion a year before. The Tokyo-based company said quarterly sales slipped 2% to JPY3.7 trillion, about GBP23.6 billion. Like the rest of the world's car makers, Honda's manufacturing has also been affected by delays due to coronavirus restrictions. Japan's top car company, Toyota, reported a similar drop in profit. Honda said it expects the challenges to persist. Rising material costs are also a problem, but the company said cost-cutting efforts have allowed it to raise its profit projection.

----------

Wednesday's shareholder meetings

Contango Holdings PLC - AGM

Euromoney Institutional Investor PLC - AGM

Finsbury Growth & Income Trust PLC - AGM

Grainger PLC - AGM

JPMorgan Asia Growth & Income PLC - AGM

Oxford MetriCredit Suisse PLC - AGM

Petra Diamonds Ltd - special meeting re framework agreement

Schroder UK Mid Cap Fund PLC - AGM

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.